Epidemiology and clinical diagnosis: Alzheimer disease

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Alzheimer disease (AD) is the sixth leading cause of death in the United States. Incidence rates increase exponentially from age 65 years on. Onset of AD before age 60 (EOAD) and at 65 years and older (LOAD) share similar postmortem findings, but vary in their clinical presentations. Therapeutic disappointments, the complex genetics of LOAD, and new findings related to regional progression of pathology have led to new hypotheses that emphasize either the vulnerability of the aging brain with respect to stress, or a neuron-to-neuron transmission process similar to what is observed in prion disorders. Mounting evidence suggests that the initial physiologic changes (preclinical phase) that place the brain on the pathway to LOAD occur at least 20 years before dementia symptoms appear. This initial preclinical phase is followed by a phase whereby cognitive impairment, but no functional impairment, is present (mild cognitive impairment), which is then followed by the third phase of dementia. Diagnosis of AD has primarily been one of exclusion of all other causes of reversible and irreversible dementia. Overlapping clinical presentations of diseases causing neurodegeneration, however, create challenges for accurate diagnosis. Use of clinical magnetic resonance and PET imaging modalities increase the specificity of diagnosis. Several new promising experimental approaches are discussed in other articles elsewhere in this issue.

Original languageEnglish
Pages (from-to)391-405
Number of pages15
JournalPET Clinics
Volume8
Issue number4
DOIs
StatePublished - Oct 2013
Externally publishedYes

Fingerprint

epidemiology
Dementia
impairment
Alzheimer Disease
Epidemiology
brain
bioelectricity
Neurons
Prions
Brain
vulnerability
causes
Cause of Death
pathology
mounting
exclusion
neurons
Magnetic Resonance Imaging
death
progressions

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Epidemiology and clinical diagnosis : Alzheimer disease. / Mackin, Robert.

In: PET Clinics, Vol. 8, No. 4, 10.2013, p. 391-405.

Research output: Contribution to journalArticle

@article{b28ed9e4f3804537a2793216cc6f6ebd,
title = "Epidemiology and clinical diagnosis: Alzheimer disease",
abstract = "Alzheimer disease (AD) is the sixth leading cause of death in the United States. Incidence rates increase exponentially from age 65 years on. Onset of AD before age 60 (EOAD) and at 65 years and older (LOAD) share similar postmortem findings, but vary in their clinical presentations. Therapeutic disappointments, the complex genetics of LOAD, and new findings related to regional progression of pathology have led to new hypotheses that emphasize either the vulnerability of the aging brain with respect to stress, or a neuron-to-neuron transmission process similar to what is observed in prion disorders. Mounting evidence suggests that the initial physiologic changes (preclinical phase) that place the brain on the pathway to LOAD occur at least 20 years before dementia symptoms appear. This initial preclinical phase is followed by a phase whereby cognitive impairment, but no functional impairment, is present (mild cognitive impairment), which is then followed by the third phase of dementia. Diagnosis of AD has primarily been one of exclusion of all other causes of reversible and irreversible dementia. Overlapping clinical presentations of diseases causing neurodegeneration, however, create challenges for accurate diagnosis. Use of clinical magnetic resonance and PET imaging modalities increase the specificity of diagnosis. Several new promising experimental approaches are discussed in other articles elsewhere in this issue.",
author = "Robert Mackin",
year = "2013",
month = "10",
doi = "10.1016/j.cpet.2013.08.001",
language = "English",
volume = "8",
pages = "391--405",
journal = "PET Clinics",
issn = "1556-8598",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Epidemiology and clinical diagnosis

T2 - Alzheimer disease

AU - Mackin, Robert

PY - 2013/10

Y1 - 2013/10

N2 - Alzheimer disease (AD) is the sixth leading cause of death in the United States. Incidence rates increase exponentially from age 65 years on. Onset of AD before age 60 (EOAD) and at 65 years and older (LOAD) share similar postmortem findings, but vary in their clinical presentations. Therapeutic disappointments, the complex genetics of LOAD, and new findings related to regional progression of pathology have led to new hypotheses that emphasize either the vulnerability of the aging brain with respect to stress, or a neuron-to-neuron transmission process similar to what is observed in prion disorders. Mounting evidence suggests that the initial physiologic changes (preclinical phase) that place the brain on the pathway to LOAD occur at least 20 years before dementia symptoms appear. This initial preclinical phase is followed by a phase whereby cognitive impairment, but no functional impairment, is present (mild cognitive impairment), which is then followed by the third phase of dementia. Diagnosis of AD has primarily been one of exclusion of all other causes of reversible and irreversible dementia. Overlapping clinical presentations of diseases causing neurodegeneration, however, create challenges for accurate diagnosis. Use of clinical magnetic resonance and PET imaging modalities increase the specificity of diagnosis. Several new promising experimental approaches are discussed in other articles elsewhere in this issue.

AB - Alzheimer disease (AD) is the sixth leading cause of death in the United States. Incidence rates increase exponentially from age 65 years on. Onset of AD before age 60 (EOAD) and at 65 years and older (LOAD) share similar postmortem findings, but vary in their clinical presentations. Therapeutic disappointments, the complex genetics of LOAD, and new findings related to regional progression of pathology have led to new hypotheses that emphasize either the vulnerability of the aging brain with respect to stress, or a neuron-to-neuron transmission process similar to what is observed in prion disorders. Mounting evidence suggests that the initial physiologic changes (preclinical phase) that place the brain on the pathway to LOAD occur at least 20 years before dementia symptoms appear. This initial preclinical phase is followed by a phase whereby cognitive impairment, but no functional impairment, is present (mild cognitive impairment), which is then followed by the third phase of dementia. Diagnosis of AD has primarily been one of exclusion of all other causes of reversible and irreversible dementia. Overlapping clinical presentations of diseases causing neurodegeneration, however, create challenges for accurate diagnosis. Use of clinical magnetic resonance and PET imaging modalities increase the specificity of diagnosis. Several new promising experimental approaches are discussed in other articles elsewhere in this issue.

UR - http://www.scopus.com/inward/record.url?scp=84885108881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885108881&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2013.08.001

DO - 10.1016/j.cpet.2013.08.001

M3 - Article

AN - SCOPUS:84885108881

VL - 8

SP - 391

EP - 405

JO - PET Clinics

JF - PET Clinics

SN - 1556-8598

IS - 4

ER -